Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis

Trends in Endocrinology and Metabolism

Volumn 21, Issue 2, 2010, Pages 59-67

  Tomas, Eva ^a   Habener, Joel F ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; EXENDIN[9-39]; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCAGON LIKE PEPTIDE 1 [9-36] AMIDE; GLUCAGON LIKE PEPTIDE 1 AGONIST; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; INSULIN; LIRAGLUTIDE; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; ARTICLE; CARDIOVASCULAR DISEASE; CELL PROTECTION; DIABETES MELLITUS; DRUG MECHANISM; FATTY LIVER; GLUCONEOGENESIS; GLUCOSE METABOLISM; HEART; HEART FAILURE; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HOMEOSTASIS; HORMONE ACTION; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; LIVER; LIVER CELL; METABOLIC SYNDROME X; MITOCHONDRION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; VASCULARIZATION; VASODILATATION;

AMINO ACID SEQUENCE; ANIMALS; BLOOD VESSELS; CYTOPROTECTION; GLUCAGON-LIKE PEPTIDE 1; HEART; HEPATOCYTES; HUMANS; INSULIN; LIVER; MODELS, BIOLOGICAL; MODELS, THEORETICAL; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTOR, INSULIN; RECEPTORS, GLUCAGON;

EID: 75249100556     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2009.11.007     Document Type: Article

References (60)

1. Kieffer T.J., and Habener J.F. The glucagon-like peptides. Endocr. Rev. 20 (1999) 876-913
2. Estall J.L., and Drucker D.J. Glucagon-like peptide-2. Annu. Rev. Nutr. 26 (2006) 391-411
3. Jiang G., and Zhang B.B. Glucagon and regulation of glucose metabolism. Am. J. Physiol. Endocrinol. Metab. 284 (2003) E671-678
4. Lovshin J.A., and Drucker D.J. Incretin-based therapies for type 2 diabetes mellitus. Nat. Rev. Endocrinol. 5 (2009) 262-269
5. Abu-Hamdah R., et al. Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides. J. Clin. Endocrinol Metab. 94 (2009) 1843-1852
6. Deacon C.F. Circulation and degradation of GIP and GLP-1. Horm. Metab. Res. 36 (2004) 761-765
7. Plamboeck A., et al. Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. Diabetologia. 48 (2005) 1882-1890
8. Drucker D.J. The biology of incretin hormones. Cell Metab. 3 (2006) 153-165
9. Drucker D.J., and Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368 (2006) 1696-1705
10. Holz IV G.G., et al. Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37). Nature 361 (1993) 362-365
11. Beinborn M., et al. A human glucagon-like peptide-1 receptor polymorphism results in reduced agonist responsiveness. Regul. Pept. 130 (2005) 1-6
12. Deacon C.F., et al. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 144 (1995) 1126-1131
13. Hansen L., et al. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 140 (1999) 5356-5363
14. Roques B.P., et al. Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. Pharmacol. Rev. 45 (1993) 87-146
15. Hupe-Sodmann K., et al. Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Regul. Pept. 58 (1995) 149-156
16. Byrne J.A., et al. Lack of hepatocellular CD10 along bile canaliculi is physiologic in early childhood and persistent in Alagille syndrome. Lab. Invest. 87 (2007) 1138-1148
17. Egan J.M., et al. Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state. J. Clin. Endocrinol. Metab. (2002) 3768-3773
18. Ryan A.S., et al. Insulinotropic hormone glucagon-like peptide-1-(7-37) appears not to augment insulin-mediated glucose uptake in young men during euglycemia. J. Clin. Endocrinol. Metab. 83 (1998) 2399-2404
19. Lee Y.S., et al. Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis. Diabetes 56 (2007) 1671-1679
20. Ding X., et al. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 43 (2006) 173-181
21. Samson S.L., et al. Gene therapy for diabetes: metabolic effects of helper-dependent adenoviral exendin 4 expression in a diet-induced obesity mouse model. Mol. Ther. 16 (2008) 1805-1812
22. Redondo A., et al. Cell signaling of the GLP-1 action in liver. Mol. Cell Endocrinol. 204 (2003) 43-50
23. Nikolaidis L.A., et al. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol. 289 (2005) H2401-H2408
24. Ban K., et al. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 117 (2008) 2340-2350
25. Ossum A., et al. The cardioprotective and inotropic components of postconditioning effects of GLP-1 and GLP-1(9-36)a in an isolated rat heart. Pharmacol. Res. 60 (2009) 411-417
26. Sonne D.P., et al. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul. Pept. 146 (2008) 243-249
27. Szeto H. Cell-permeable, mitochondrial-targeted, peptide antioxidants. AAPS J. 21 (2006) E277-283
28. Wu D., et al. A highly potent peptide analgesic that protects against ischemia-reperfusion-induced myocardial stunning. Am. J. Physiol. Heart Circ. Physiol. 283 (2002) H783-791
29. Song W., et al. A potent opiate agonist protects against myocardial stunning during myocardial ischemia and reperfusion in rats. Coron. Artery Dis. 16 (2005) 407-410
30. Green B.D., et al. GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP. Arch. Biochem. Biophys. 478 (2008) 136-142
31. Nathanson D., et al. Endothelial dysfunction induced by triglycerides is not restored by exenatide in rat conduit arteries ex vivo. Regul. Pept. 157 (2009) 8-13
32. Elahi D., et al. Glucagon-like peptide-1 (9-36) amide, cleavage product of glucagon-like peptide-1 (7-36) is a glucoregulatory peptide. Obesity 16 (2008) 1501-1509
33. Vahl T.P., et al. Effects of GLP-1-(7-37), and GLP-1-(9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans. J. Clin. Endocrinol. Metab. 88 (2003) 1772-1779
34. Randle P.J. Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years. Diabetes Metab. Rev. 14 (1998) 263-283
35. Vahl T.P., et al. Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. Endocrinology 148 (2007) 4965-4973
36. Inonut V., et al. Exenatide can reduce glucose independent of islet hormones or gastric emptying. Am. J. Physiol. Endocrinol. Metab. 295 (2008) E269-277
37. Sandoval D.A., et al. Arcuate glucagon-line peptide 1 receptors regulate glucose homeostasis but not food intake. Diabetes 57 (2008) 2046-2054
38. Nishizawa M., et al. The hepatic vagal reception of intraportal GLP-1 is via receptor different from the pancreatic GLP-1 receptor. J. Auton. Nerv. Syst. 80 (2000) 14-21
39. Dardevet D., et al. Insulin secretion-independent effects of GLP-1 on canine liver glucose metabolism do not involve portal vein GLP-1 receptors. Am. J. Physiol Gastrointest. Liver Physiol. 289 (2005) G806-814
40. Villanueva-Penacarillo M.L., et al. Glucagon-like peptide-1 binding to rat hepatic membranes. J. Endocrinol. 146 (1995) 183-189
41. Li W.C., et al. In vitro transdifferentiation of hepatoma cells into functional pancreatic cells. Mech. Dev. 122 (2005) 837-847
42. Aviv V., et al. Exendin-4 promotes liver cell proliferation and enhances PDX-1-induced liver to pancreas transdifferentiation. J. Biol. Chem. 284 (2009) 33509-33520
43. Bullock B.P., et al. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 137 (1996) 2968-2978
44. Blackmore P.F., et al. Absence of insulinotropic glucagon-like peptide-1(7-37) receptors on isolated rat liver hepatocytes. FEBS Lett. 283 (1991) 7-10
45. Flock G., et al. Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice. Diabetes 56 (2007) 3006-3013
46. Korner M., et al. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vitro targeting. J. Nucl. Med. 48 (2007) 736-743
47. Horbinski C., and Chu C.T. Kinase signaling cascades in the mitochondrion: a matter of life or death. Free Radic. Biol. Med. 38 (2005) 2-11
48. Affaitati A., et al. Essential role of A-kinase anchor protein 121 for cAMP signaling to mitochondria. J. Biol. Chem. 278 (2003) 4286-4294
49. Bijur G.N., and Jope R.S. Rapid accumulation of Akt in mitochondria following phosphatidylinositol 3kinase activation. J. Neurochem. 87 (2003) 1427-1435
50. Demers A., et al. Identification of the growth hormone-releasing peptide binding site in CD36: a photoaffinity cross-linking study. Biochem. J. 382 (2004) 417-424
51. Moore K.J., et al. A CD36-initiated signaling cascade mediates inflammatory effects of beta-amyloid. J. Biol. Chem. 277 (2002) 47373-47379
52. Isenberg J.S., et al. Thrombospondin-1 inhibits nitric oxide signaling via CD36 by inhibiting myristic acid uptake. J. Biol. Chem. 282 (2007) 15404-15415
53. Lemire B.D., et al. The mitochondrial targeting function of randomly generated peptide sequences correlates with predicted helical amphiphilicity. J. Biol. Chem. 264 (1989) 20205-20215
54. Yamada H., et al. Mitochondrial targeting sequence of the influenza A virus PB1-F2 protein and its function in mitochondria. FEBS Lett. 578 (2004) 331-336
55. Brun C., et al. Intracellular targeting of truncated secretory peptides in the mammalian heart and brain. FASEB J. 20 (2006) 732-734
56. Chen Y., et al. Lysine propionylation and butyrylation are novel post-translational modifications in histones. Mol. Cell Proteomics. 6 (2007) 812-819
57. Chauvin S., et al. Palmitoylation of stathmin family proteins domain A controls Golgi versus mitochondrial subcellular targeting. Biol. Cell 100 (2008) 577-589
58. Duvnjak M., et al. Pathogenesis and management issues for non-alcoholic fatty liver disease. World J. Gastroenterol. 13 (2007) 4539-4550
59. Maiese K., et al. Mechanistic insights into diabetes mellitus and oxidative stress. Curr. Med. Chem. 14 (2007) 1729-1738
60. Park T.S., et al. Lipids in the heart: a source of fuel and a source of toxins. Curr. Opin. Lipidol. 18 (2007) 277-282